CD20 Inhibitors & Biosimilars
15 drugsAbout CD20
B-Lymphocyte Antigen CD20 (MS4A1) is a transmembrane protein expressed on B cells. It regulates B-cell activation and proliferation, making it a key target for immune-mediated diseases and B-cell lymphomas.
CD20 is a clinically validated drug target, though genetic evidence linking CD20 variations to specific diseases is moderate (max score 0.48). Activation of CD20 is likely beneficial based on genetic data.
CD20 is targeted by 15 FDA-approved drugs, including TRUXIMA, RITUXAN and OCREVUS. These drugs include antibodies (6), other biologics (6), and bispecific antibodies (3), primarily for oncology indications.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- Emerging modalities (Antibody) signal innovation opportunity.
- phase1 represents biological uncertainty with 55% completion.
CD20 Genetic Evidence Moderate
Genetic evidence provides moderate support for CD20 as a drug target (max score 0.48).
Further research into the genetic associations with vitamin B deficiency could reveal novel therapeutic opportunities.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 1 traits
- • Strong signal in immune system disease, hematologic disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
3 totalGWAS and other genetic studies link MS4A1 to 3 diseases.
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 20 strong
max H4: 0.99eQTL/pQTL signals for MS4A1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top CD20 Drugs
Eight companies have approved CD20-targeting drugs, with Novartis, CELLTRION INC, and Roche leading the market.
The presence of multiple players suggests a competitive market, but also opportunities for strategic partnerships or acquisitions.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| RUXIENCE | Pfizer | 2019 | 8 |
| ARZERRA | Novartis | 2009 | 4 |
| RITUXAN HYCELA | Roche | 2017 | 3 |
| EPKINLY | GENMAB US, INC. | 2023 | 3 |
| GAZYVA | Roche | 2013 | 3 |
| KESIMPTA | Novartis | 2009 | 3 |
| BRIUMVI | TG THERAPEUTICS, INC | 2022 | 3 |
| COLUMVI | Roche | 2023 | 2 |
| OCREVUS | Roche | 2017 | 2 |
| OCREVUS ZUNOVO | Roche | 2024 | 1 |
| LUNSUMIO | Roche | 2022 | 1 |
| ZEVALIN | SPECTRUM PHARMS | 2002 | 1 |
CD20 Drug Modality Landscape
Modalities
Routes of Administration
CD20 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
The bispecific antibody modality represents a growing segment, suggesting an opportunity for novel therapeutic approaches.
📈 Modality Evolution
Antibodies pioneered CD20 targeting (1997), with bispecific antibodies entering more recently (2022).
CD20 Clinical Trials 1,761 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 497 | 206 | 113 | 174 | 65% |
| Phase 2 | 850 | 313 | 151 | 381 | 67% |
| Phase 3 | 337 | 137 | 55 | 145 | 71% |
| Phase 4 | 77 | 40 | 11 | 25 | 78% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved CD20 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CD20. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
CD20 Drug Approval Timeline (1997 - 2024)
The first CD20-targeting drug was approved in 1997, with the most recent approval in 2024.
The continued approvals indicate sustained interest in CD20 as a target, but also suggest increasing market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 8 companies competing
- • Market share by company
Full Drug Portfolio
- • All 15 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 15-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 1138 clinical trials targeting CD20.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities